Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F22%3AE0109851" target="_blank" >RIV/00843989:_____/22:E0109851 - isvavai.cz</a>
Alternative codes found
RIV/61988987:17110/22:A2302J5E
Result on the web
<a href="https://aacrjournals.org/clincancerres/article-abstract/28/21/4771/709838/Circulating-Tumor-and-Immune-Cells-for-Minimally?redirectedFrom=fulltext" target="_blank" >https://aacrjournals.org/clincancerres/article-abstract/28/21/4771/709838/Circulating-Tumor-and-Immune-Cells-for-Minimally?redirectedFrom=fulltext</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1158/1078-0432.CCR-22-1594" target="_blank" >10.1158/1078-0432.CCR-22-1594</a>
Alternative languages
Result language
angličtina
Original language name
Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma
Original language description
Purpose: Early intervention in smoldering multiple myeloma (SMM) requires optimal risk stratification to avoid under- and overtreatment. We hypothesized that replacing bone marrow (BM) plasma cells (PC) for circulating tumor cells (CTC), and adding immune biomarkers in peripheral blood (PB) for the identification of patients at risk of progression due to lost immune surveillance, could improve the International Myeloma Working Group 20/2/20 model. Experimental design: We report the outcomes of 150 patients with SMM enrolled in the iMMunocell study, in which serial assessment of tumor and immune cells in PB was performed every 6 months for a period of 3 years since enrollment. Results: Patients with >0.015% versus ?0.015% CTCs at baseline had a median time-to-progression of 17 months versus not reached (HR, 4.9; P < 0.001). Presence of >20% BM PCs had no prognostic value in a multivariate analysis that included serum free light-chain ratio >20, >2 g/dL M-protein, and >0.015% CTCs. The 20/2/20 and 20/2/0.015 models yielded similar risk stratification (C-index of 0.76 and 0.78). The combination of the 20/2/0.015 model with an immune risk score based on the percentages of SLAN+ and SLAN- nonclassical monocytes, CD69+HLADR+ cytotoxic NK cells, and CD4+CXCR3+ stem central memory T cells, allowed patient' stratification into low, intermediate-low, intermediate-high, and high-risk disease with 0%, 20%, 39%, and 73% rates of progression at 2 years. Conclusions: This study showed that CTCs outperform BM PCs for assessing tumor burden. Additional analysis in larger series are needed to define a consensus cutoff of CTCs for minimally invasive stratification of SMM.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Clinical cancer research
ISSN
1078-0432
e-ISSN
1557-3265
Volume of the periodical
28
Issue of the periodical within the volume
21
Country of publishing house
US - UNITED STATES
Number of pages
11
Pages from-to
4771-4781
UT code for WoS article
000892375100001
EID of the result in the Scopus database
2-s2.0-85141003981